Mateon Therapeutics (OTCMKTS:MATN) Stock Crosses Above 200 Day Moving Average – Should You Sell?

Mateon Therapeutics, Inc. (OTCMKTS:MATN) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.07 and traded as high as $0.0894. Mateon Therapeutics shares last traded at $0.0894, with a volume of 24,773 shares traded.

Mateon Therapeutics Price Performance

The stock has a market capitalization of $8.07 million, a P/E ratio of -4.47 and a beta of 1.33. The stock’s fifty day moving average is $0.09 and its two-hundred day moving average is $0.07.

Mateon Therapeutics Company Profile

Mateon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies that selectively target tumor tissue. The company’s platform leverages tumor-activated peptides designed to bind to the fibrin–fibronectin complexes uniquely present in solid tumors, with the goal of improving the therapeutic index of cytotoxic payloads while limiting off-target effects.

Its lead asset, MH1, is a peptide–drug conjugate in Phase I clinical trials for advanced solid tumors.